Citations

Clear

1444 citation(s) found for "Petersen, Ronald".

Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline
Aakre, Jeremiah A. , Proctor, Nicholas K. , Eichenlaub, Udo, Vemuri, Prashanthi , Graff‐Radford, Jonathan, Jack, Clifford R. , Petersen, Ronald C. , Dage, Jeffrey L. , Jack, Clifford R , Vemuri, Prashanthi , Dage, Jeffrey L , Mielke, Michelle M. , Algeciras‐Schimnich, Alicia , Machulda, Mary M. , Knopman, David S. , Graff‐Radford, Jonathan

Mayo Clinic

Alzheimer's & Dementia | July 26, 2021 | Volume: 18 | Issue: 4 | Pages: 602-611

10.1002/alz.12415 | PMID 34310832 Get It

AbstractIntroductionThe prognostic utility of cerebrospinal fluid (CSF) phosphorylated tau 217 (p‐tau217) and p‐tau181 is not understood.MethodsAnalyses included 753 Mayo Clinic Study on Aging participants (median age = 71.6; 57% male). CSF amyloid beta (Aβ)42 and p‐tau181 were measured with Elecsys immunoassays. CSF p‐tau181 and p‐tau217 were also measured with Meso Scale Discovery (MSD). We used Cox proportional hazards models for risk of mild cognitive impairment (MCI) and linear mixed models for risk of global and domain‐specific cognitive decline and cortical thickness. Analyses were stratified by elevated brain amyloid based on CSF Aβ42 or amyloid positron emission tomography for those with imaging.ResultsCSF p‐tau217 was superior to p‐tau181 for the diagnosis of Alzheimer's disease (AD) pathology. CSF MSD p‐tau181 and p‐tau217 were associated with risk of MCI among amyloid‐positive individuals. Differences between CSF p‐tau measures predicting cortical thickness were subtle.DiscussionThere are subtle differences for CSF p‐tau217 and p‐tau181 as prognostic AD markers.
Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
Harten, Argonde C. van , Wiste, Heather J. , Weigand, Stephen D. , Kremers, Walter K. , Eichenlaub, Udo, Dyer, Roy B. , Jack, Clifford R. , Petersen, Ronald C. , van Harten, Argonde C, Jack, Clifford R , Kremers, Walter K , Mielke, Michelle M. , Algeciras‐Schimnich, Alicia , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | July 26, 2021 | Volume: 18 | Issue: 4 | Pages: 635-644

10.1002/alz.12406 | PMID 34310035 Get It

Abstract Introduction We aimed to provide cut points for the automated Elecsys Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers. Methods Cut points for Elecsys amyloid beta 42 (Aβ42), total tau (t‐tau), hyperphosphorylated tau (p‐tau), and t‐tau/Aβ42 and p‐tau/Aβ42 ratios were evaluated in Mayo Clinic Study of Aging (n = 804) and Mayo Clinic Alzheimer's Disease Research Center (n = 70) participants. Results The t‐tau/Aβ42 and p‐tau/Aβ42 ratios had a higher percent agreement with normal/abnormal amyloid positron emission tomography (PET) than the individual CSF markers. Reciever Operating Characteristic (ROC)‐based cut points were 0.26 (0.24–0.27) for t‐tau/Aβ42 and 0.023 (0.020–0.025) for p‐tau/Aβ42. Ratio cut points derived from other cohorts performed as well in our cohort as our own did. Individual biomarkers had worse diagnostic properties and more variable results in terms of positive and negative percent agreement (PPA and NPA). Conclusion CSF t‐tau/Aβ42 and p‐tau/Aβ42 ratios are very robust indicators of AD. For individual biomarkers, the intended use should determine which cut point is chosen.
Participation of persons with dementia and their caregivers in research
Frank, Lori , Jennings, Lee A. , Petersen, Ronald C. , Majid, Tabassum , Schicker, Lonni, Karlawish, Jason , Gilmore‐Bykovskyi, Andrea L

Mayo Clinic

Journal of the American Geriatrics Society | July 10, 2021 | Volume: 69 | Issue: 7 | Pages: 1784-1792

10.1111/jgs.17340 | PMID 34245586 Get It

Abstract Background The National Institute on Aging, in conjunction with the Department of Health and Human Services as part of the National Alzheimer's Project Act, convened a 2020 National Research Summit on Care, Services, and Supports for Persons with Dementia and their Caregivers . This review article addresses research participation by persons living with dementia (PLWD) and their care partners in two different ways: as research participants with input on outcomes studied and as engaged research partners. Results This article summarizes each of the topics presented at this Summit session, followed by reflection from the session panelists. Lee Jennings examined collection of outcomes directly from PLWD and the potential for individualized outcomes to enhance measurement in intervention trials. Ron Petersen discussed the impact of nomenclature on research and clinical care, and how and why investigators should be mindful of the connection between dementia nomenclature and the conduct of dementia research. Tabassum Majid examined strategies for engagement in research, including specific examples of involving PLWD and their care partners (including staff in assisted living and skilled nursing facilities), and the potential for this research engagement to improve our understanding of interventions in dementia. Conclusions Research participation by PLWD and their care partners is evolving. This review summarizes three areas of opportunity and steps for researchers to work with PLWD and their care partners to design and conduct research that enhances knowledge based on what we learn from PLWD and their care partners, and creates knowledge with them.
Abstract 44: Associations of Atrial Fibrillation, Neuroimaging Measures of Cerebrovascular Disease and Alzheimer’S Disease-related Pathology, and Cognitive Impairment
Graff‐Radford, Jonathan , Roberts, Rosebud O., Madhavan, Malini , Cha, Ruth, Lowe, Val J. , Gunter, Jeffrey L. , Petersen, Ronald C. , Rabinstein, Alejandro A. , Vemuri, Prashanthi , Kantarci, Kejal , Mielke, Michelle M. , Senjem, Matthew L. , Pankratz, V. Shane , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 46 | Issue: suppl_1 | Pages: No page available

10.1161/str.46.suppl_1.44 Get It

The objective of this study was to investigate the cross-sectional associations of atrial fibrillation with neuroimaging measures of cerebrovascular disease and Alzheimer’s disease-related pathology, and their interaction with cognitive impairment. MRI scans of non-demented individuals (n=1044) from the population-based Mayo Clinic Study of Aging were analyzed for infarctions, total grey matter, hippocampal and white matter hyperintensity volumes. A subset of 496 individuals underwent FDG and C-11 Pittsburgh compound B (PiB) PET scans. We assessed the associations of atrial fibrillation with i) categorical MRI measures (cortical and subcortical infarctions) using multivariable logistic regression models, and with ii) continuous MRI measures ( hippocampal, total grey matter, and white matter hyperintensity volumes) and FDG-PET and PiB-PET measures using multivariable linear regression models, and adjusting for confounders. Among participants who underwent MRI (median age, 77.8, 51.6% male), 13.5% had atrial fibrillation. Presence of atrial fibrillation was associated with subcortical infarctions (odds ratio [OR], 1.83; p=0.002), cortical infarctions (OR, 1.91; p=0.03), total grey matter volume (Beta [β], -.025, p<.0001) after controlling for age, education, gender, APOE e4 carrier status, coronary artery disease, diabetes, history of clinical stroke, and hypertension. However, atrial fibrillation was not associated with white matter hyperintensity volume, hippocampal volume, Alzheimer’s pattern of FDG hypometabolism or PiB uptake. There was a significant interaction of cortical infarction (p for interaction=0.004) and subcortical infarction (p for interaction =0.015) with atrial fibrillation with regards to odds of mild cognitive impairment (MCI). Using subjects with no atrial fibrillation and no infarction as the reference, the OR (95% confidence intervals [CI]) for MCI was 2.98 (1.66, 5.35;p = 0.0002) among participants with atrial fibrillation and any infarction, 0.69 (0.36, 1.33;p= 0.27) for atrial fibrillation and no infarction, and 1.50 (0.96, 2.32;p = 0.07) for no atrial fibrillation and any infarction. These data highlight that atrial fibrillation is associated with MCI in the presence of infarctions.
Abstract WMP57: Declining Blood Pressure is Associated with Subcortical Microinfarcts in Older Adults
Raman, Mekala R., Graff‐Radford, Jonathan , Przybelski, Scott A. , Lesnick, Timothy G. , Roberts, Rosebud O., Petersen, Ronald C. , Parisi, Joseph E., Mielke, Michelle M. , Boeve, Bradley F. , Knopman, David S. , Dickson, Dennis W. , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Stroke | June 21, 2021 | Volume: 48 | Issue: suppl_1 | Pages: No page available

10.1161/str.48.suppl_1.wmp57 Get It

Hypertension is highly prevalent in the elderly population and microinfarcts are the most common vascular brain pathology identified in older adults at autopsy. We investigated the associations between systolic and diastolic blood pressures measured antemortem and the presence of microinfarcts at autopsy. Study subjects (n=302; age range=71-95) were participants in the population-based Mayo Clinic Study of Aging autopsy study, who had blood pressure measurements recorded during life. We investigated both cross-sectional systolic and diastolic blood pressure measurements at the baseline visit and the change in blood pressure (slope). Presence and location (subcortical or cortical) of chronic microinfarcts was abstracted from the autopsy reports. Of the 302 study subjects, 47 (16%) had cerebral microinfarcts, and, of those, 18 (38%) had subcortical microinfarcts and 29 (62%) had only cortical microinfarcts. The baseline blood pressures were not different between subjects with no microinfarcts, subcortical microinfarcts, and only cortical microinfarcts. In a logistic regression model including time between last blood pressure measurement and death, a greater decline in systolic [OR= 1.06 (1.01, 1.11); p=0.02]) and greater decline in diastolic [OR= 1.11 (1.02, 1.20); p=0.01] blood pressures were predictors of the presence of subcortical microinfarcts at autopsy. However, these variables were not associated with the presence of cortical microinfarcts. In conclusion, microinfarcts are common in the older adult population, and most of them are located in the cortex. A greater decline in both systolic and diastolic blood pressures and their association with subcortical microinfarcts, but not with cortical microinfarcts, may have implications for aggressive lowering of blood pressure in the elderly population.
Abstract WMP102: Prevalence and Natural History of Superficial Siderosis: A Population-based Study
Pichler, Michael, Brown, Robert D. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Flemming, Kelly D. , Rabinstein, Alejandro A. , Kantarci, Kejal , Vemuri, Prashanthi , Mielke, Michelle M. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Stroke | June 21, 2021 | Volume: 48 | Issue: suppl_1 | Pages: No page available

10.1161/str.48.suppl_1.wmp102 Get It

Introduction: Cortical superficial siderosis (cSS) refers to deposition of blood breakdown products along the cerebral cortex, causing characteristic staining patterns seen with iron-sensitive MRI techniques. Cortical superficial siderosis is a relatively rare disorder, but has been linked to cerebral amyloid angiopathy and Alzheimer’s disease. The objective of this study was to determine the frequency and natural history of cSS in the general elderly population. Methods: MRI scans from the Mayo Clinic Study of Aging (MCSA), an ongoing population-based study of elderly residents in Olmsted County, Minnesota, were reviewed by neuroradiologists. Participants with cSS were identified based on linear pattern of hypointensity on gradient recalled echo imaging consistent with cSS. Exclusion criteria were: 1) MRI findings not consistent with cSS or 2) alternative explanation for MRI findings (such as aneurysmal subarachnoid hemorrhage, intracranial surgery, or trauma). Additional data abstracted included extent of cSS, presence of cerebral microbleeds, and clinical outcome. Results: Eleven out of 1,441 participants had MRI scans showing cSS (0.8%). When stratified by age, the frequency was 0.4% in those 50 to 70 years old and 1.1% in those over 70 years old. Six participants had only focal involvement of cSS (restricted to three or fewer sulci) and five had disseminated involvement (affecting more than three sulci). Microbleeds were seen in four of five (80%) participants with disseminated cSS, but none with focal cSS. Five participants (2 focal, 3 disseminated cSS) had follow up MRI scans, with an average follow up of 25 months. There was no further hemorrhage in those with focal cSS. However, all three participants with disseminated cSS experienced additional hemorrhage: one with new microbleeds, one with new microbleeds and lobar hemorrhage, and one with sulcal subarachnoid hemorrhage and lobar hemorrhage. Conclusion: Although rare, cSS may be encountered in the general elderly population. Extent of involvement of cSS and concomitant microbleeds may be important risk factors for progression of disease and intracerebral hemorrhage. The clinical significance of focal cSS occurring in the absence of microbleeds requires further investigation.
Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks
Schumacher, Julia , Gunter, Jeffrey L. , Przybelski, Scott A. , Graff‐Radford, Jonathan , Savica, Rodolfo , Senjem, Matthew L. , Jack, Clifford R. , Lowe, Val J. , Fields, Julie A. , Kremers, Walter K. , Petersen, Ronald C. , Graff‐Radford, Neill R. , Ferman, Tanis J. , Thomas, Alan , Kantarci, Kejal, Kantarci, Kejal , Graff-Radford, Jonathan , Boeve, Brad , Graff-Radford, Neill R , Jack, Clifford R , Thomas, Alan J , Taylor, John Paul , Senjem, Matthew L , Kantarci, Kejal , Ferman, Tanis J , Kremers, Walter K , Jones, David T. , Schwarz, Christopher G. , Knopman, David S. , Boeve, Bradley F. , Taylor, John‐Paul

Mayo Clinic

Brain | June 9, 2021 | Volume: 144 | Issue: 10 | Pages: 3212-3225

10.1093/brain/awab218 | PMID 34114602 Get It

Abstract Dementia with Lewy bodies (DLB) is neuropathologically defined by the presence of α-synuclein aggregates, but many DLB cases show concurrent Alzheimer’s disease pathology in the form of amyloid-β plaques and tau neurofibrillary tangles. The first objective of this study was to investigate the effect of Alzheimer’s disease co-pathology on functional network changes within the default mode network (DMN) in DLB. Second, we studied how the distribution of tau pathology measured with PET relates to functional connectivity in DLB. Twenty-seven DLB, 26 Alzheimer’s disease and 99 cognitively unimpaired participants (balanced on age and sex to the DLB group) underwent tau-PET with AV-1451 (flortaucipir), amyloid-β-PET with Pittsburgh compound-B (PiB) and resting-state functional MRI scans. The resing-state functional MRI data were used to assess functional connectivity within the posterior DMN. This was then correlated with overall cortical flortaucipir PET and PiB PET standardized uptake value ratio (SUVr). The strength of interregional functional connectivity was assessed using the Schaefer atlas. Tau-PET covariance was measured as the correlation in flortaucipir SUVr between any two regions across participants. The association between region-to-region functional connectivity and tau-PET covariance was assessed using linear regression. Additionally, we identified the region with highest and the region with lowest tau SUVrs (tau hot- and cold spots) and tested whether tau SUVr in all other brain regions was associated with the strength of functional connectivity to these tau hot and cold spots. A reduction in posterior DMN connectivity correlated with overall higher cortical tau- (r = −0.39, P = 0.04) and amyloid-PET uptake (r = −0.41, P = 0.03) in the DLB group, i.e. patients with DLB who have more concurrent Alzheimer’s disease pathology showed a more severe loss of DMN connectivity. Higher functional connectivity between regions was associated with higher tau covariance in cognitively unimpaired, Alzheimer’s disease and DLB. Furthermore, higher functional connectivity of a target region to the tau hotspot (i.e. inferior/medial temporal cortex) was related to higher flortaucipir SUVrs in the target region, whereas higher functional connectivity to the tau cold spot (i.e. sensory-motor cortex) was related to lower flortaucipir SUVr in the target region. Our findings suggest that a higher burden of Alzheimer’s disease co-pathology in patients with DLB is associated with more Alzheimer’s disease-like changes in functional connectivity. Furthermore, we found an association between the brain’s functional network architecture and the distribution of tau pathology that has recently been described in Alzheimer’s disease. We show that this relationship also exists in patients with DLB, indicating that similar mechanisms of connectivity-dependent occurrence of tau pathology might be at work in both diseases.
Cognitive Impairment and Dementia After Stroke: Design and Rationale for the DISCOVERY Study
Rost, Natalia S. , Meschia, James F. , Wruck, Lisa , Helmer, Karl G. , Greenberg, Steven M. , Investigators*, on behalf of the DISCOVERY, Barrett, Kevin M. , Biffi, Alessandro , Fornage, Myriam , Etherton, Mark R. , Golland, Polina , Graff-Radford, Jonathan, Jack, Cliff R, Kalpathy–Cramer, Jayashree , Kittner, Steven J. , Lowe, Val J. , Petersen, Ronald C. , Sherman, Alexander , Viswanathan, Anand , Meschia, James F , Wruck, Lisa M , Gottesman, Rebecca F. , Investigators*, on behalf of the DISCOVERY, Boden-Albala, Bernadette M , Graff‐Radford, Jonathan , Hinman, Jason D. , Knopman, David S. , Manly, Jennifer J. , Mosley, Thomas H. , Rissman, Robert A. , Schirmer, Markus D. , Schwab, Kristin , Seshadri, Sudha , Sherman, Alexander, Vemuri, Prashanthi

Mayo Clinic

Stroke | May 27, 2021 | Volume: 52 | Issue: 8 | Pages: No page available

10.1161/strokeaha.120.031611 | PMID 34039035 Get It

Stroke is a leading cause of the adult disability epidemic in the United States, with a major contribution from poststroke cognitive impairment and dementia (PSCID), the rates of which are disproportionally high among the health disparity populations. Despite the PSCID’s overwhelming impact on public health, a knowledge gap exists with regard to the complex interaction between the acute stroke event and highly prevalent preexisting brain pathology related to cerebrovascular and Alzheimer disease or related dementia. Understanding the factors that modulate PSCID risk in relation to index stroke event is critically important for developing personalized prognostication of PSCID, targeted interventions to prevent it, and for informing future clinical trial design. The DISCOVERY study (Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery), a collaborative network of thirty clinical performance clinical sites with access to acute stroke populations and the expertise and capacity for systematic assessment of PSCID will address this critical challenge. DISCOVERY is a prospective, multicenter, observational, nested-cohort study of 8000 nondemented ischemic and hemorrhagic stroke patients enrolled at the time of index stroke and followed for a minimum of 2 years, with serial cognitive evaluations and assessments of functional outcome, with subsets undergoing research magnetic resonance imaging and positron emission tomography and comprehensive genetic/genomic and fluid biomarker testing. The overall scientific objective of this study is to elucidate mechanisms of brain resilience and susceptibility to PSCID in diverse US populations based on complex interplay between life-course exposure to multiple vascular risk factors, preexisting burden of microvascular and neurodegenerative pathology, the effect of strategic acute stroke lesions, and the mediating effect of genomic and epigenomic variation.
MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease
Chen, Qin , Arani, Arvin , Senjem, Matthew L. , Jack, Clifford R. , Przybelski, Scott A. , Lesnick, Timothy G. , Kremers, Walter K. , Fields, Julie A. , Gunter, Jeffrey L. , Trzasko, Joshua D. , Graff‐Radford, Jonathan, Savica, Rodolfo , Ferman, Tanis J. , Graff‐Radford, Neill R., Petersen, Ronald C. , Kantarci, Kejal , Arani, Arvin , Jack, Clifford R , Senjem, Matthew L , Kantarci, Kejal , Ferman, Tanis J , Kremers, Walter K , Boeve, Bradley F. , Schwarz, Christopher G. , Graff‐Radford, Jonathan , Knopman, David S. , Dickson, Dennis W. , Graff‐Radford, Neill R.

Mayo Clinic

Journal of Neuroimaging | May 25, 2021 | Volume: 31 | Issue: 5 | Pages: 1020-1027

10.1111/jon.12878 | PMID 34033185 Get It

ABSTRACT Background and Purpose Neurodegeneration of the substantia nigra in Lewy body disease is associated with iron deposition, which increases the magnetic susceptibility of the substantia nigra on MRI. Our objective was to measure iron deposition in the substantia nigra in patients with probable dementia with Lewy bodies (pDLB) and patients who are at risk for pDLB by quantitative susceptibility mapping (QSM). Methods Participants included pDLB ( n = 36), mild cognitive impairment with at least one core feature of DLB (MCI‐LB; n = 15), idiopathic rapid eye movement sleep behavior disorder (iRBD; n = 11), and an age‐and gender‐matched clinically unimpaired control group ( n = 102). QSM was derived from multi‐echo 3D gradient recalled echo MRI at 3T, and groups were compared on mean susceptibility values of the substantia nigra and its relation to parkinsonism severity. Results Patients with pDLB had higher susceptibility in the substantia nigra compared to controls ( p < 0.001) and MCI‐LB ( p = 0.043). The susceptibility of substantia nigra showed an increasing trend from controls to iRBD and MCI‐LB, and to pDLB ( p < 0.001). Parkinsonism severity was not associated with the mean susceptibility in the substantia nigra in the patient groups. Conclusions Our data suggested that QSM is sensitive to the increased magnetic susceptibility due to higher iron content in the substantia nigra in pDLB. The trend of increasing susceptibility from controls to iRBD and MCI‐LB, and to pDLB suggests that iron deposition in the substantia nigra starts to increase as early as the prodromal stage in DLB and continues to increase as the disease progresses, independent of parkinsonism severity.
Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition
Raghavan, Sheelakumari , Przybelski, Scott A. , Lesnick, Timothy G. , Graff‐Radford, Jonathan , Mielke, Michelle M. , Petersen, Ronald C. , Jack, Clifford R. , Vemuri, Prashanthi , Graff-Radford, Jonathan , Mielke, Michelle M , Vemuri, Prashanthi , Jack, Clifford R , Reid, Robert I. , Schwarz, Christopher G. , Knopman, David S. , Machulda, Mary M.

Mayo Clinic

Brain Communications | May 18, 2021 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcab106 | PMID 34136811 Get It

Abstract White matter microstructure undergoes progressive changes during the lifespan, but the neurobiological underpinnings related to ageing and disease remains unclear. We used an advanced diffusion MRI, Neurite Orientation Dispersion and Density Imaging, to investigate the microstructural alterations due to demographics, common age-related pathological processes (amyloid, tau and white matter hyperintensities) and cognition. We also compared Neurite Orientation Dispersion and Density Imaging findings to the older Diffusion Tensor Imaging model-based findings. Three hundred and twenty-eight participants (264 cognitively unimpaired, 57 mild cognitive impairment and 7 dementia with a mean age of 68.3 ± 13.1 years) from the Mayo Clinic Study of Aging with multi-shell diffusion imaging, fluid attenuated inversion recovery MRI as well as amyloid and tau PET scans were included in this study. White matter tract level diffusion measures were calculated from Diffusion Tensor Imaging and Neurite Orientation Dispersion and Density Imaging. Pearson correlation and multiple linear regression analyses were performed with diffusion measures as the outcome and age, sex, education/occupation, white matter hyperintensities, amyloid and tau as predictors. Analyses were also performed with each diffusion MRI measure as a predictor of cognitive outcomes. Age and white matter hyperintensities were the strongest predictors of all white matter diffusion measures with low associations with amyloid and tau. However, neurite density decrease from Neurite Orientation Dispersion and Density Imaging was observed with amyloidosis specifically in the temporal lobes. White matter integrity (mean diffusivity and free water) in the corpus callosum showed the greatest associations with cognitive measures. All diffusion measures provided information about white matter ageing and white matter changes due to age-related pathological processes and were associated with cognition. Neurite orientation dispersion and density imaging and diffusion tensor imaging are two different diffusion models that provide distinct information about variation in white matter microstructural integrity. Neurite Orientation Dispersion and Density Imaging provides additional information about synaptic density, organization and free water content which may aid in providing mechanistic insights into disease progression.